Quantitative counseling after genetic testing in breast cancer: the GET FACTS randomized clinical trial

Increasing germline genetic testing rates may impact contralateral prophylactic mastectomy (CPM) rates in patients with newly diagnosed breast cancer. The GET FACTS randomized clinical trial at the Dana-Farber Cancer Institute (Boston, MA), aimed to quantify the impact of a personalized contralateral breast cancer (CBC) risk counseling tool that incorporates genetic testing results. In this trial of 346 patients aged 18 to 80 years with unilateral breast cancer, those randomized to quantitative counseling with a visual decision support tool more accurately reported their CBC risk compared with those randomized to standard counseling. However, no differences in the propensity toward or uptake of CPM was found between the 2 study arms. The authors conclude that these findings suggest that patients who were counseled with a personalized CBC risk tool were better informed of their CBC risk, although being better informed did not appear to impact CPM decisions (visual abstract).